ReViral
ReViral is a UK-based biotechnology company with a portfolio of drugs to treat Respiratory Syncytial Virus (RSV) infection. RSV currently represents a major unmet medical need in children, the elderly and the immuno compromised.
Our most advanced programme, RV521, is a highly potent, orally-administered inhibitor of RSV fusion protein, and has demonstrated top-line safety and pharmacokinetic data in Phase1 single and multiple ascending dose (SAD and MAD) trials. RV521 has successfully completed a Phase 2a proof-of-concept study in adult volunteers. RV521 will start clinical trials in patients in 2018.
Follow @ReViral_ltd
Plenty of incidence of #RespiratorySyncytialVirus infection (14.7%) in this #pediatric study of influenza-like illness (ILI) from the Gambia 🇬🇲... #EndRSV #virus Viral Etiology, Clinical Features and Antibiotic Use in Children pubmed.ncbi.nlm.nih.gov/32453201/
See other Cell and Gene organisations
-
Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual ... -
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4 (MAGE-A4), ADP-A2M10 (MAGE-A10), ... -
Aglaris Ltd produce equipment to ensure cell and tissue culture is an easy, problem-free task. -
Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer ...
Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.
Learn moreCopyright © 2020 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.